Antimicrobial treatment of anaerobic infections

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 11, 2011, Pages 1691-1707

  Brook, Itzhak ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaerobes; Antibiotics; Bacteroides; Clostridium; Fusobacterium; Peptostreptoccci; Prevotella

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CARBAPENEM; CARBENICILLIN; CEFOXITIN; CEFTRIAXONE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; DORIPENEM; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; IMIPENEM; LINCOMYCIN; MEROPENEM; METRONIDAZOLE; MEZLOCILLIN; MINOCYCLINE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SPIRAMYCIN; TICARCILLIN; TIGECYCLINE; TINIDAZOLE; TROVAFLOXACIN; UNINDEXED DRUG;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ACTINOMYCES; AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ANAEROBIC INFECTION; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ATAXIA; BACTERIAL STRAIN; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES UNIFORMIS; BACTEROIDES VULGATUS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; COLITIS; COMMUNITY ACQUIRED PNEUMONIA; CONVULSION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG PENETRATION; DRUG SAFETY; ENTAMOEBA HISTOLYTICA; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; GIARDIA LAMBLIA; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; KLEBSIELLA PNEUMONIAE; LIPID SOLUBILITY; LUNG INFECTION; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NAUSEA; NEUTROPENIA; NONHUMAN; OPTIC NEURITIS; PARVIMONAS MICRA; PERIPHERAL NEUROPATHY; PHLEBITIS; PORPHYROMONADACEAE; PROPIONIBACTERIUM ACNES; PSEUDOMONAS AERUGINOSA; REVIEW; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TREATMENT RESPONSE; TRICHOMONAS VAGINALIS; VERTIGO; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 79960281577     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.576672     Document Type: Review

References (113)

1. Hecht DW. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe 2006;12:115-21 (Pubitemid 43831678)
2. Kaide CG, Khandelwal S. Hyperbaric oxygen: applications in infectious disease. Emerg Med Clin North Am 2008;26:571-95 (Pubitemid 351491562)
3. Barnes RC. Point: hyperbaric oxygen is beneficial for diabetic foot wounds. Clin Infect Dis 2006;43:188-92
4. Cimsit M, Uzun G, Yildiz S. Hyperbaric oxygen therapy as an anti-infective agent. Expert Rev Anti Infect Ther 2009;7:1015-26
5. Brook I. Microbiology and antimicrobial management of head and neck infections in children. In: Kappy MS, Accurso FJ, Barness LA, et al. editors. Advances in pediatrics. Elsevier-Mosby, Philadelphia, PA; 2008. p. 305-25
6. Brook I. Anaerobic infections diagnosis and management. A textbook. Informa Healthcare USA, Inc., New York; 2007
7. Sweet RL. Treatment strategies for pelvic inflammatory disease. Expert Opin Pharmacother. 2009;10:823-37
8. Mazuski JE, Solomkin JS. Intra-abdominal infections. Surg Clin North Am 2009;89:421-37
9. Finegold SM, George WL, Mulligan ME. Anaerobic infections. Disease a month. Volume 31. Yearbook Medical Publisher, Inc., Chicago; 1985
10. Verklin RM, Mandell GL. Alteration of antibiotics by anaerobiosis. J Lab Clin Med 1977;89:65-71
11. Gorbach SL, Bartlett JG. Anaerobic infections. N Engl J Med 1974;290:1177-84
12. Singer E, Calvet L, Mory F, et al. Monitoring of antibiotic resistance of gram negative anaerobes. Med Mal Infect 2008;38:256-63
13. Glupczynski Y, Berhin C, Nizet H. Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by E-test methodology. Eur J Clin Microbiol Infect Dis 2009;28:261-7
14. Roh KH, Kim S, Kim CK, et al. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997 - 2004, in Korea. Korean J Lab Med 2009;29:293-8
15. Seifert H, Dalhoff A; PRISMA Study Group. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study. J Antimicrob Chemother 2010;65:2405-10
16. Snydman DR, Jacobus NV, McDermott LA, et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005 - 2007). Clin Infect Dis 2010;50(Suppl 1):S26-33
17. Labbe AC, Bourgault AM, Vincelette J, et al. Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada. Antimicrob Agents Chemother 1999;43:2517-19 (Pubitemid 29471238)
18. Fernández Canigia L, Castello L, Di Martino A, et al. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina. Rev Argent Microbiol 2007;39:156-60 (Pubitemid 47616109)
19. Nagy E, Urbán E, Nord CE; on behalf of the ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2011;17:371-9
20. Liu CY, Huang YT, Liao CH, et al. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008;52:3161-8
21. Finegold SM. Anaerobic bacteria in human disease. Academic Press, New York; 1977
22. Goldstein EJC, Citron DM. Resistance trends in antimicrobial susceptibility of anaerobic bacteria. Clin Micro Newslett 2011;33:1-16
23. Finegold SM. In vitro efficacy of beta-lactam/beta-lactamase inhibitor combinations against bacteria involved in mixed infections. Int J Antimicrob Agents 1999;12(Suppl 1):S9-14 (Pubitemid 29371828)
24. Acuna C, Rabasseda X. Amoxicillinsulbactam: a clinical and therapeutic review. Drugs Today (Barc) 2001;37:193-210
25. Sutter VL, Finegold SM. Susceptibility of anaerobic bacteria to carbenicillin, cefoxitin, and related drugs. J Infect Dis 1975;131:417-22
26. Fiedelman W, Webb CD. Clinical evaluation of carbenicillin in the treatment of infection due to anaerobic bacteria. Curr Ther Res Clin Exp 1975;18:441-51
27. Thadepalli H, Huang JT. Treatment of anaerobic infections: carbenicillin alone compared with clindamycin and gentamicin. Curr Ther Res 1977;22:549-57
28. Brook I. Carbenicillin in treatment of aspiration pneumonia in children. Curr Ther Res 1978;23:136-47 (Pubitemid 8286927)
29. Brook I. Anaerobic isolates in chronic recurrent suppurative otitis media: treatment with carbenicillin alone and in combination with gentamicin. Infection 1979(5):247-51 (Pubitemid 10197457)
30. Tally FP, Jacobus NV, Bartlett JG, Gorbach SL. In vitro activity of penicillins against anaerobes. Antimicrob Agents Chemother 1975;7:413-14
31. Roy I, Bach V, Thadepalli H. In vitro activity of ticarcillin against anaerobic bacteria compared with that of carbenicillin and penicillin. Antimicrob Agents Chemother 1977;11:258-61 (Pubitemid 8042478)
32. Powell LL, Wilson SE. The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Surg Infect 2000;1:57-63
33. Jousimies-Somer H, Summanen P. Recent taxonomic changes and terminology update of clinically significant anaerobic gram-negative bacteria (excluding spirochetes). Clin Infect Dis 2002;35(Suppl 1):S17-21
34. Jousimies-Somer HR, Summanen P, Baron EJ, et al. Wadsworth-KTL anaerobic bacteriology manual. 6th edition. Star Publishing, Belmont, CA; 2002
35. Brook I. Microbiology and management of abdominal infections. Dig Dis Sci 2008;53:2585-91
36. Goldstein EJ. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. Clin Infect Dis 2002;35(Suppl 1):S106-111
37. Hedberg M, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003;9:475-88 (Pubitemid 36833791)
38. Lucasti C, Jasovich A, Umeh O, et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008;30:868-83 (Pubitemid 351799866)
39. Goulenok TM, Majed K, Monchi M. Role and impact of carbapenem in nosocomial infections. Recent Pat Antiinfect Drug Discov 2011;6:45-53
40. Bassetti M, Nicolini L, Esposito S, et al. Current status of newer carbapenems. Curr Med Chem 2009;16:564-75
41. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008;47(Suppl 1):S32-40
42. Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin Microbiol Infect 2008;14:1102-111
43. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005;65:2151-78 (Pubitemid 41478796)
44. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009;49:291-8
45. Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc 1999;74:825-33 (Pubitemid 29362591)
46. Thadepalli H, Gorbach SL, Bartlett JG. Apparent failure of chloramphenicol in anaerobic infections. Obstet Gynecol Surv 1978;35:334-5
47. Balbi HJ. Chloramphenicol: a review. Pediatr Rev 2004;25:284-8 (Pubitemid 38988991)
48. Nau R, Sorgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet 1998;35:223-46 (Pubitemid 28430036)
49. Drutz DJ, Schaffner W, Hillman JW, Koenig MG. The penetration of penicillin and other antimicrobials into joint fluid. J Bone Joint Surg Am 1967;49:1415-21
50. Joiner KA, Lowe BR, Dzink JL, Bartlett JG. Antibiotic levels in infected and sterile subcutaneous abscesses in mice. J Infect Dis 1981;143:487-94 (Pubitemid 11113671)
51. Goldstein EJ, Citron DM, Merriam CV. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob Agents Chemother 1999;43:1469-74 (Pubitemid 29259346)
52. Williams JD, Maskell JP, Shain H, et al. Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J Antimicrob Chemother 1992;30:27-37
53. Sanai Y, Persson GR, Starr JR, et al. Presence and antibiotic resistance of Porphyromonas gingivalis, Prevotella intermedia, and Prevotella nigrescens in children. J Clin Periodontol 2002;29:929-34 (Pubitemid 41697784)
54. Finegold SM, Harada NE, Miller LG. Lincomycin activity against anaerobes and effect on normal human fecal flora. Antimicrob Agents Chemother (Bethesda) 1965(5):659-67
55. Aldridge KE, Ashcraft D, Cambre K, et al. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001;45:1238-43 (Pubitemid 32231006)
56. Klainer AS. Clindamycin. Med Clin North Am 1987;71:1169-75 (Pubitemid 18052320)
57. Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 1990;19:280-318
58. Feigin RD, Pickering LK, Anderson D, et al. Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatrics 1975;55:213-23
59. Novak E, Wagner JG, Lamb DJ. Local and systemic tolerance, absorption and excretion of clindamycin hydrochloride after intramuscular administration. Int Z Klin Pharmakol Ther Toxikol 1970;3:201-8
60. Panzer JD, Brown DC, Epstein WL, et al. Clindamycin levels in various body tissues and fluids. J Clin Pharmacol New Drugs 1972;12:259-62
61. Gorbach SL, Thadepalli H. Clindamycin in the treatment of pure and mixed anaerobic infections. Arch Intern Med 1974;134:87-92
62. Gorbach SL. Antibiotics and Clostridium difficile. N Engl J Med 1999;341:1690-1
63. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile - associated diarrhea: a review. Arch Intern Med 2001;161:525-33 (Pubitemid 32167517)
64. Devenyi AG. Antibiotic-induced colitis. Semin Pediatr Surg 1995;4:215-20
65. Berlatzky Y, Rubin SZ, Michel J, et al. Use of clindamycin and gentamicin in pediatric colonic surgery. J Pediatr Surg 1976;11:94-83
66. Brook I. Clindamycin in treatment of aspiration pneumonia in children. Antimicrob Agents Chemother 1979;15:342-4
67. Brook I. Bacteriology and treatment of chronic otitis media in children. Laryngoscope 1979;89:1129-34 (Pubitemid 10189864)
68. Brook I, Yocum P. Antimicrobial management of chronic sinusitis in children. J Laryngol Otol 1995;109:1159-62 (Pubitemid 26003161)
69. Brook I, Lewis MA, Sandor GK, et al. Clindamycin in dentistry: more than just effective prophylaxis for endocarditis?. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:550-8 (Pubitemid 41483637)
70. Lofmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 2010;50(Suppl 1):S16-23
71. Rustia M, Shubik P. Experimental induction of hematomas, mammary tumors and other tumors with metronidazole in noninbred Sas: WRC (WT)BR rats. J Natl Cancer Inst 1979;63:863-8 (Pubitemid 10225018)
72. Cohen SM, Erturk E, Von Esch AM, et al. Carcinogenicity of 5-nitro-furans 5-nitromidazoles, 4-nitrobenzenes and related compounds. J Natl Cancer Inst 1973;51:403-17
73. Beard CM, Noller KL, OFallon WM, et al. Lack of evidence for cancer due to use of metronidazole. N Engl J Med 1979;301:519-22 (Pubitemid 9258259)
74. Celik A, Aras Ates N. The frequency of sister chromatid exchanges in cultured human peripheral blood lymphocyte treated with metronidazole in vitro. Drug Chem Toxicol 2006;29:85-94 (Pubitemid 43292237)
75. Friedman GD, Jiang SF, Udaltsova N, et al. Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity. Int J Cancer 2009;125:2173-18
76. Brook I. Treatment of anaerobic infections in children with metronidazole. Dev Pharmacol Ther 1983;6:187-98 (Pubitemid 13120265)
77. Toft Sørensen H, Larsen H, Snitker Jensen E, et al. Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J Antimicrob Chemother 1999;44:854-5
78. Nord CE, Oprica C. Antibiotic resistance in Propionibacterium acnes. Microbiological and clinical aspects. Anaerobe 2006;12:207-10 (Pubitemid 44666468)
79. Nicolau DP. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opin Pharmacother 2009;10:1213-22
80. Goldstein EJ, Citron DM, Merriam CV, et al. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob Agents Chemother 2006;50:3507-13 (Pubitemid 44527540)
81. Appelbaum PC. Quinolone activity against anaerobes. Drugs 1999;58:60-4 (Pubitemid 29500088)
82. Stein GE, Goldstein EJ. Fluoroquinolones and anaerobes. Clin Infect Dis 2006;42:1598-607
83. Blondeau JM, Sanche SE. Quinupristin/ dalfopristin. Expert Opin Pharmacother 2002;3:1341-6
84. Brook I. Pathogenicity and management of polymicrobial infections due to aerobic and anaerobic bacteria. Med Res Rev 1995;15:73-82
85. Concia E, Viscoli C. Antimicrobial management of intra-abdominal infections. J Chemother 2009;21(Suppl 1):39-43
86. Holzheimer RG, Dralle H. Antibiotic therapy in intra-abdominal infections - a review on randomised clinical trials. Eur J Med Res 2001;30:277-91
87. Tellado JM, Wilson SE. Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems. Surg Infect (Larchmt) 2005;6:329-43 (Pubitemid 41645599)
88. Sanabria A. Decision-making analysis for selection of antibiotic treatment in intra-abdominal infection using preference measurements. Surg Infect (Larchmt) 2006;7:453-62 (Pubitemid 44857098)
89. Laterre PF, Colardyn F, Delmee M, et al.; IDAB. Antimicrobial therapy for intra-abdominal infections: guidelines from the Infectious Disease Advisory Board (IDAB). Acta Chir Belg 2006;106:2-21 (Pubitemid 43416668)
90. Marshall JC. Intra-abdominal infections. Microbes Infect 2004;6:1015-25 (Pubitemid 39166044)
91. Giamarellou H, Kanellakopoulou K. Bacteriologic and therapeutic considerations in intra-abdominal surgical infections. Anaerobe 1997;3:207-112
92. Kaniga K, Flamm R, Tong SY, et al. Worldwide experience with the use of doripenem against extended-spectrumbeta- lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. Antimicrob Agents Chemother 2010;54:2119-24
93. Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother 2007;8:237-56 (Pubitemid 46206625)
94. Munckhof WJ, Carney J, Neilson G, et al. Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2005;25:514-22 (Pubitemid 40732606)
95. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-6
96. Brook I, Coolbaugh JC, Walker RI, Weiss E. Synergism between penicillin, clindamycin or metronidazole and gentamicin against species of Bacteroides melaninogenicus and fragilis groups. Antimicrob Agents Chemother 1984;25:71-7 (Pubitemid 14223547)
97. Acar JF. Antibiotic synergy and antagonism. Med Clin North Am 2000;84:1391-406
98. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997 - 2000. Clin Infect Dis 2002;35(Suppl 1):S126-34
99. Bergan T, Fotland MH. In vitro interactions between metronidazole or tinidazole and co-trimoxazole on the effect against anaerobic bacteria. Scand J Gastroenterol Suppl 1984;19(Suppl):95-101 (Pubitemid 14140436)
100. Ralph ED, Amatnieks YE. Potentially synergistic antimicrobial combinations with metronidazole against Bacteroides fragilis. Antimicrob Agents Chemother 1980;17:379-82 (Pubitemid 10094309)
101. Busch DF, Sutter VL, Finegold SM. Activity of combinations of antimicrobial agents against Bacteroides fragilis. J Infect Dis 1976;133-321-8
102. Brook I. Metronidazole and spiramycin in abscesses caused by Bacteroides sp. Staphylococcus aureus in mice. J Antimicrob Chemother 1987;20:713-18 (Pubitemid 18036586)
103. Videau D, Blanchard JC, Sebald M. Bucco-dental flora. Sensitivity to antibiotics and value of the spiramycin-metronidazole combination. Ann Microbiol (Paris) 1973;1248:505-16
104. Ednie LM, Credito KL, Khantipong M, et al. Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods. J Antimicrob Chemother 2000;45:633-8 (Pubitemid 30255643)
105. Credito KL, Jacobs MR, Appelbaum PC. Anti-anaerobic activity of levofloxacin alone and combined with clindamycin and metronidazole. Diagn Microbiol Infect Dis 2000;38:181-3
106. Fass RJ, Rotilie CA, Prior RB. Interaction of clindamycin and gentamicin in vitro. Antimicrob Agents Chemother 1974;6.582-7
107. Okubadejo OA, Allen J. Combined activity of clindamycin and gentamicin on Bacteroides fragilis and other bacteria. J Antimicrob Chemother 1975;1:403-9
108. Brook I, Walker RI. Interaction between penicillin, clindamycin or metronidazole and gentamicin against species of clostridia and anaerobic and facultative anaerobic Gram-positive cocci. J Antimicrob Chemother 1985;15:31-7 (Pubitemid 15097540)
109. Bryan LE, Kowand SK, Den Elzen HM. Mechanisms of aminoglycoside antibiotic resistance in anaerobic bacteria: Clostridium perfringens and Bacteroides fragilis. Antimicrob Agents Chemother 1979;15:7-13 (Pubitemid 9099624)
110. Delgado G Jr, Barletta JF, Kanji S, et al. Characteristics of prophylactic antibiotic strategies after penetrating abdominal trauma at a level I urban trauma center: a comparison with the East guidelines. J Trauma 2002;53:673-8 (Pubitemid 35190597)
111. Petersen K, Waterman P. Prophylaxis and treatment of infections associated with penetrating traumatic injury. Expert Rev Anti Infect Ther 2011;9:81-96
112. Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 2010;51:1306-13
113. Brook I. Actinomycosis: diagnosis and management. South Med J 2008;101:1019-23